Efficacy and Safety of Cyclophosphamide Low-Dose Pre-Phase Chemotherapy in Diffuse Large B Cell Lymphoma with Gastrointestinal Involvement.
Cyclophosphamide
Diffuse Large B Cell Lymphoma with gastrointestinal involvement
Low-dose pre-phase chemotherapy
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
09
2021
accepted:
06
02
2022
entrez:
21
4
2022
pubmed:
22
4
2022
medline:
22
4
2022
Statut:
epublish
Résumé
Gastric Diffuse large B-cell lymphoma (DLBCL) is the most common extranodal site of lymphoma's involvement (30%-40% of all extranodal lymphomas and 55%-65% of all gastrointestinal lymphomas). However, gastric localizations are also sometimes found in systemic DLBCL. Gastric complications such as bleeding, perforation, and stenosis under chemotherapy are well documented. We retrospectively analyzed 15 patients with newly diagnosed DLBCL with gastrointestinal involvement. Endoscopies were performed in these patients before and after treatment. Treatment consisted of cyclophosphamide low-dose pre-phase chemotherapy before conventional-dose chemotherapy. Endoscopy at staging detected ulcers in 12 patients (80%). After low-dose pre-phase chemotherapy, GI ulcers healed in 91.6% of cases (1 ulcer detected). After the whole treatment (Low-dose pre-phase + chemotherapy) 9 patients (60%) achieved complete response, 4 patients (26.6%) partial response, 2 (13,3%) patients presented disease progression. The most frequent adverse event was neutropenia (73.3%); the most frequent non-hematological adverse event was transaminases elevation (20%). Cyclophosphamide low-dose pre-phase chemotherapy resulted in a safe and effective way to prevent adverse events in systemic DLBCL with gastrointestinal involvement.
Sections du résumé
Background
UNASSIGNED
Gastric Diffuse large B-cell lymphoma (DLBCL) is the most common extranodal site of lymphoma's involvement (30%-40% of all extranodal lymphomas and 55%-65% of all gastrointestinal lymphomas). However, gastric localizations are also sometimes found in systemic DLBCL. Gastric complications such as bleeding, perforation, and stenosis under chemotherapy are well documented.
Methods
UNASSIGNED
We retrospectively analyzed 15 patients with newly diagnosed DLBCL with gastrointestinal involvement. Endoscopies were performed in these patients before and after treatment. Treatment consisted of cyclophosphamide low-dose pre-phase chemotherapy before conventional-dose chemotherapy.
Results
UNASSIGNED
Endoscopy at staging detected ulcers in 12 patients (80%). After low-dose pre-phase chemotherapy, GI ulcers healed in 91.6% of cases (1 ulcer detected). After the whole treatment (Low-dose pre-phase + chemotherapy) 9 patients (60%) achieved complete response, 4 patients (26.6%) partial response, 2 (13,3%) patients presented disease progression. The most frequent adverse event was neutropenia (73.3%); the most frequent non-hematological adverse event was transaminases elevation (20%).
Conclusion
UNASSIGNED
Cyclophosphamide low-dose pre-phase chemotherapy resulted in a safe and effective way to prevent adverse events in systemic DLBCL with gastrointestinal involvement.
Identifiants
pubmed: 35444769
doi: 10.4084/mjhid.2022.017
pii: mjhid-14-1-e2022017
pmc: PMC8992639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2022017Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest. Compliance with Ethical Standards. Disclosure of potential conflicts of interest: The authors did not receive support from any organization for the submitted work. The authors have no relevant financial or non-financial interests to disclose. Ethics Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from all individual participants included in the study.
Références
Ann Hematol. 2012 Nov;91(11):1731-9
pubmed: 22752193
Curr Treat Options Oncol. 2018 Jun 21;19(8):38
pubmed: 29931605
Blood. 2006 Jan 1;107(1):265-76
pubmed: 16150940
J Hematol Oncol. 2020 Jun 6;13(1):71
pubmed: 32505213
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Cancer Genet. 2018 Dec;228-229:28-40
pubmed: 30553470
Am Soc Clin Oncol Educ Book. 2015;:e449-57
pubmed: 25993209
Pathol Int. 2016 Aug;66(8):444-52
pubmed: 27439595
World J Gastroenterol. 2004 Jan;10(1):5-11
pubmed: 14695759
Ann Surg Oncol. 2006 Nov;13(11):1372-8
pubmed: 17009162
Cancer. 1980 Jul 1;46(1):215-22
pubmed: 7388763
Cancer Manag Res. 2020 Jun 25;12:5041-5048
pubmed: 32612391
J Trace Elem Med Biol. 2019 May;53:1-7
pubmed: 30910191
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
J Gastrointest Oncol. 2012 Sep;3(3):209-25
pubmed: 22943012
Leuk Lymphoma. 2015;56(9):2613-8
pubmed: 25676238
World J Gastroenterol. 2011 Feb 14;17(6):697-707
pubmed: 21390139
J Clin Oncol. 1988 Jul;6(7):1125-33
pubmed: 3392561
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877